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Introduction
High blood pressure and proteinuria are main risk factors for end-stage renal disease (1). 
Blood pressure control is therefore a cornerstone in prevention of progressive renal function 
loss, together with reduction of proteinuria. Moreover, renal patients are  also at particularly 
high cardiovascular risk (2). Recent studies provided evidence that even mild renal function 
impairment is associated with an elevated cardiovascular risk (3-5). This unfavorable risk 
profile in the renal patient prompts us to invest great effort to improve overall prognosis by 
optimal blood pressure control as well as additional measures.
Recent studies provided new insights into the optimal blood pressure target in renal patients 
and into the specific renoprotective effects of different classes of antihypertensive drugs. We 
will expand on these optimal targets by addressing the impact of individual differences in 
therapy response. These individual differences - that we will denote as “response variability” 
- reflect an important, but underrated phenomenon: for any intervention - even of proven effi-
cacy - individual differences in therapeutic benefit are large. Exploration of the mechanisms 
underlying these differences in responsiveness to therapy may allow important progress in 
improving prognosis in renal patients.
Target blood pressure in renal patients
Whereas the unfavorable cardiovascular risk profile in renal function impairment is well-
established, the optimal target blood pressure for overall risk reduction in renal patients has 
not prospectively been investigated so f ar. The HOT study, designed to establish the benefits 
of a lower target diastolic blood pressure (< 90 vs <85 vs <80 mmHg) for cardiovascular events 
in a total of 18,790 hypertensive patients, also included 470 subjects with serum creatinine 
between 1.5 – 3.0 mg/dl at entry (4). The adjusted relative risk for major cardiovascular events 
was 2.05 (95% CI 1.47-2.88) in subjects with renal function impairment, in spite of similar blood 
pressure. There was a tendency towards benefit of the lower blood pressure target in patients 
with renal function impairment, but this did not reach statistical significance. However, the 
study was not powered for the purpose of analyzing the data in the renal patients specifically. 
As to the target blood pressure for renoprotection, the Modification of Diet in Renal Disease 
trial remains a landmark study (6). This trial is still the only prospective study evaluating the 
value of low target blood pressure in renal patient, in addition to the effect of low protein 
diet. The secondary analysis (7) from the trial convincingly demonstrated that the severity 
of proteinuria before treatment is the main determinant of the benefit of obtaining lower 
target blood pressure. When proteinuria was 1-3 g/day, a mean arterial pressure of 98 mmHg 
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was absent if proteinuria was less than 1 g/day. Moreover, in patients with proteinuria > 
3g/day an additional benefit was found for an even lower blood pressure: a mean arterial 
pressure of 92 mmHg (125/75 mmHg). Thus, higher proteinuria before treatment is a prompt 
for a lower target blood pressure.
The importance of blood pressure control for renoprotection was confirmed by a recent 
meta-analysis, demonstrating a linear association between obtained blood pressure and rate 
of renal function loss across nine intervention studies (8), with no apparent J-curve. Thus, 
rigorous blood pressure control should be pursued in renal patients. It is to be noted, that 
the reduction of proteinuria at onset of antihypertensive therapy - and residual proteinuria 
during therapy - consistently predicts the subsequent rate of renal function loss (9-11). 
In addition to blood pressure control, reduction of proteinuria is an excellent surrogate 
parameter for long term renoprotection. Therefore, it was recommended that, in addition to 
blood pressure, treatment should be titrated on reduction of proteinuria (12).
As proteinuria is a major cardiovascular risk factor as well, it would be logical to expect that 
benefit of a lower blood pressure on cardiovascular end-points would also be more readily 
apparent in proteinuric patients, in particular as reduction of proteinuria is associated with 
an improvement of lipid profile (13). So far, no data on hard end-points are available to 
support this assumption, but new guidelines already anticipate and suggest treatment goals 
less than 130/80 for patients with renal disease (JNC7) (14).
Choice of antihypertensive regimen
All currently available classes of antihypertensives can be used in renal patients. As to 
antihypertensive efficacy, there is no specific benefit of one class over another (15), 
although one would intuitively favor diuretics. Usually combination treatment is required 
to obtain blood pressure control. As reduction of proteinuria predicts renoprotective bene-
fit, regimens that specifically reduce proteinuria have advantages for renoprotection. 
Effective antihypertensive regimens generally also lower proteinuria, with the exception of 
dihydropyridine calcium channel blockers (16). Blockade of the renin-angiotensin-aldosterone 
system (RAAS), by ACE inhibition or AT1-blockade, has specific antiproteinuric properties in 
addition to the antihypertensive effect, which is likely to account for their additional efficacy 
in renoprotection (10;17-19). Whilst this is particularly apparent in populations with overt 




As treatment should be guided by optimal reduction of blood pressure and proteinuria, 
therapy should be titrated towards these goals. Several considerations are important. 
Sodium status
In spite of the proven renoprotective potential of RAAS-blockade, its efficacy is consistently 
blunted by sodium overload. The blunted efficacy during conditions of sodium excess was 
noted already early after introduction of ACE inhibitors in clinical practice (21), and has 
been documented in essential hypertensives as well as proteinuric patients. Dietary sodium 
restriction, or co-treatment with a diuretic should therefore be applied if therapy response 
is insufficient (22;23).
Considering that the unfavorable effect of high sodium intake on the response to ACE 
inhibition has been known for almost two decades, and considering the important place of 
ACE inhibitors in the therapeutic arsenal, it may be somewhat surprising that the mechanism 
of this blunting is still largely unknown.
Optimal dosing
Dose is also important to consider. Animal experiments suggest that doses of ACE inhibitors 
higher than needed for optimal blood pressure control, induce additional renoprotection (24). 
Data in humans seem to be consistent with this finding, as the optimal dose of ACE inhibitors 
and AT1 blockade for specific renal effects (as estimated from proteinuria reduction) appears 
to be higher than the optimal antihypertensive dose in many patients. Conversely, an 
antiproteinuric dose response can be present without effects on blood pressure, particularly 
in normotensive patients (25). Recent data from Laverman et al show that the dose response 
for blood pressure reduction with Angiotensin-II-receptor-antagonist may be different for 
the antiproteinuric response (in press Kidney Int Suppl 2004). Taken together, these data 
suggest that dose response for blood pressure and for specific renal effects may not be the 
same, notwithstanding the antiproteinuric effect of reduction of blood pressure.
Combination regimens
Considering the therapeutic benefits of both ACE inhibition and AT1 blockade, several studies 
addressed their combination, assuming that RAAS blockade at different levels simultaneously 
might result in more effective blockade, and thus afford greater therapeutic benefit. In non-
insulin-dependent diabetes mellitus the combination of lisinopril and candesartan was more 
effective than either drug as a monotherapy after 12 weeks of treatment (26). However, as 
relatively low doses were used, similar effects might well have been obtained by increasing 
the dose of the single agents. In renal patients small studies suggest an added effect of dual 
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blockade, but these studies did not test the single drugs at the top of their dose-response 
either (27-29). A large recent study in Japan, the COOPERATE trial, however, found a reduced 
risk in patients treated with a combination of both fixed high dose trandolapril and losartan 
compared to high dose of trandolapril or losartan alone (30). Blood pressure level was 
maintained below 130/80 during the study using all non RAAS blocking agents and was 
similar in all groups during the complete study. However, in the group treated with dual 
RAAS blockade proteinuria was significantly more reduced compared to a similar reduction 
in either mono-therapy group. The differences in renoprotection are probably due to this 
much larger antiproteinuric effect of dual blockade. Laverman et al have shown individual 
dose-dependent differences in maximum reduction of proteinuria (31). A combination of 
both maximally effective ACE inhibition and AT1-blokade reduced both proteinuria as well 
as blood pressure further than one agent alone. Thus, a more individualized approach could 
further increase renoprotection. This individual approach is discussed in more detail below. 
Individual response variability
Individual determinants of therapy response. 
Even for regimens of well-established benefit at group level, interindividual differences in 
therapeutic benefit are often considerable. The usual aim in hypertension and renal disease 
trials is to obtain a statistically significant effect at group level. From this perspective, 
response variability between patients is a confounding factor prompting for larger studies, 
in order to obtain statistical significance in spite of the individual differences. Older as well 
as recent studies, however, suggest that it might be fruitful not to focus exclusively on what 
groups of patients have in common, but also to explore the mechanisms underlying the 
differences between patients, as this might define better targets for intervention. (32;33)
Evidence for individual determinants of therapy response in hypertension was elegantly 
provided by Dickerson et al (34) who applied a rotation schedule testing four classes of 
antihypertensive drugs in each patient. Patients with a good response to ACE inhibition 
also responded well to beta-blockade, whereas no correlation with the response to diuretic 
or calcium channel blocker was found. So far, no similar studies were performed in renal 
patients. However, we performed together with Parving’s group a 2-class rotation protocol 
with ACE inhibition and AT1-blockade in non-diabetic and diabetic proteinuric patients (33). 
In this study, both ACE inhibition and AT1- blockade effectively reduced blood pressure 
and proteinuria at group level in non-diabetic and diabetic patients. Analysis of individual 
data revealed, first, a large variability in responsiveness between individuals, ranging from 
an excellent response to absence of response for both drugs. Remarkably, the individual 
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pressure and proteinuria. Additive information was obtained studying different doses of 
both drugs. Whereas increasing the dose of the ACE inhibitor from 10 to 20 mg enhanced the 
blood pressure response at group level, patients with an absent or poor response remained 
relatively poor responders (figure 1b).
Thus, in terms of therapy response, differences between patients by far exceeded the 
differences between the drugs, and between the different doses. This implicates that 
exploration of the mechanisms underlying these individual differences has great potential to 
improve responsiveness to therapy, and consequently long-term prognosis. 
It is important to realize that, from an individual perspective, many basic issues remain 
to be explored. There is hardly any knowledge, for instance, on individual differences in 
dose response to renoprotective drugs. We do not know, for instance, whether there are 
individuals that would benefit from higher doses than normally used and how to recognize 
them. In our opinion, the impressive difference between individuals prompts us to address 
these questions.    
Will genetic factors provide the answer? 
As illustrated above, patient factors are important in response variability. Which factors could 
be involved? It was proposed long ago that differences in response to specific intervention 
reflect the patients’ individual pathophysiological characteristics (32). Both genetic and 
environmental factors (e.g.: severity of pretreatment renal damage (35), duration of disease, 
dietary habits, and co-morbidity) and their interaction may be involved. Clearly, therapy 
A 
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Figure 1 a) Individual response to different drugs; poor responders stay poor responders b) Individual response to 
different doses; poor responders stay poor responders
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response is a complex phenomenon. The exploration of individual determinants of therapy 
response got new momentum from the developments in genetics (36). Differences in genetic 
make-up have long been known to modify drug metabolism (namely, slow versus rapid 
acetylators of hydralazine) but recently the number of studies demonstrating an association 
between pharmacodynamics and genetic factors increased dramatically (37).
The basic concept of genetic determinants of therapy response is simple: a drug interacts 
with its biological target, for instance a drug receptor. When a genetic alteration leads to 
a modified target, the response is modified as well. Thus, it would be possible to predict 
therapy response from single genetic variants. Whereas this may apply to certain animal 
models (38) and to selected conditions (39), it is becoming increasingly clear that therapy 
response should be considered a complex phenotype, rather than a simple phenotype. This 
makes sense, as therapy response is not only determined by one-way drug-target interaction, 
but also by many other biological factors, such as activity of multiple counter regulatory and 
backup pathways. The concept is illustrated by recent studies on the genetic determinants 
of the blood pressure response to thiazides. Elegant studies from Bianchi’s group not only 
demonstrated an association between the alpha-adducin polymorphism and the response 
to diuretics, but also provided possible cellular mechanisms involved (40;41). These 
investigators also demonstrated interaction between alpha-adducin genotype and ACE (I/D) 
genotype in volume regulation (42). Finally, they recently showed that ACE genotype also 
affects the response to thiazide (43) This line of evidence seems to refute the single-gene 
model for the response to thiazides, and points to the characteristics of volume regulation as 
a main intermediate factor between genetic factors and therapy response.     
Considering the importance of RAAS blocking therapy, not surprisingly many studies 
examined the effects of genetic polymorphisms in the RAAS as possible determinants of 
therapy response. ACE insertion/deletion polymorphism has so far was the most extensively 
investigated, and this has been reviewed elsewhere (44). As the deletion polymorphism is 
associated with the level of circulating and tissue ACE (45;46), it would seem logical to 
expect that ACE genotype modifies the response to ACE inhibition. The available association 
studies, however, display large discrepancies as reviewed by Boonstra et al (44) and by 
Danser and Schunkert (47). We attempted to clarify these discrepancies by not only analy-
zing for interaction between ACE genotype and therapy response, but by also taking into 
account sodium intake, as a well known modifier of the response to ACE inhibition. The 
study of Van der Kleij et al (48) provided the first evidence (albeit post-hoc) for gene-
environment interaction between the ACE genotype and sodium intake, as shown in figure 
2 for blood pressure response (the response of proteinuria was concordant). These data 
suggest that sodium dependency of the response to ACE inhibition depends on genotype. 
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Moreover, they suggest that sodium restriction blunts the impact of ACE genotype on 
therapy response, as with low sodium intake therapy response was similar in ACE insertion/
insertion and ACE deletion/deletion homozygotes. This interaction between sodium intake 
and ACE genotype was supported by prospective data in healthy volunteers (49) and in 
patients with uncomplicated type I diabetes (50). Whereas this interaction cannot explain 
all discrepancies, it illustrates the advantage of analyzing pharmacogenetic issues from 
a pathophysiological angle rather than by mere association.Considering the relationship 
between RAAS and volume status, focusing on the interaction between sodium status and 
the pathophysiological consequences of genetic polymorphisms of the RAAS may prove 
fruitful (51).
Conclusions
Rigorous blood pressure control is important in renal patients to protect against the high risk 
for renal and cardiovascular damage. So far, there are no indications of a J-curve. Particular 
attention should be given to reduction of proteinuria. Proteinuria warrants lower target blood 
pressures for renoprotection: whether lower targets will also provide additional protection 
against cardiovascular damage remains to be investigated, although there is some evidence 
emerging (52). The individual differences in responsiveness to antihypertensive therapy 
are considerable, even for interventions of proven benefit at group level. Exploration of 
the mechanisms underlying individual determinants of therapy response, and the design of 
individual strategies for optimization of therapy response should in the coming years guide 
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